---
title: "BioNTech's revenue in the second quarter was €260.8 million, estimated at €137.9 million. The loss p"
description: "BioNTech's revenue in the second quarter was €260.8 million, estimated at €137.9 million. The loss per share in the second quarter was €1.6, estimated loss was €1.41"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/251434589.md"
published_at: "2025-08-04T10:46:54.000Z"
---

# BioNTech's revenue in the second quarter was €260.8 million, estimated at €137.9 million. The loss p

> BioNTech's revenue in the second quarter was €260.8 million, estimated at €137.9 million. The loss per share in the second quarter was €1.6, estimated loss was €1.41

BioNTech's revenue in the second quarter was €260.8 million, estimated at €137.9 million.  
The loss per share in the second quarter was €1.6, estimated loss of €1.41

### Related Stocks

- [BNTX.US - BioNTech SE](https://longbridge.com/en/quote/BNTX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 隨着南卡羅來納州麻疹病例的增加，FDA 的 Makary 支持接種麻疹疫苗 | 美國食品藥品監督管理局局長馬丁·馬卡里呼籲美國人接種麻疹疫苗，因為南卡羅來納州正經歷嚴重疫情，已報告 950 例病例，主要發生在未接種疫苗的人羣中。馬卡里強調了麻腮風疫苗的重要性，建議兒童在 12 個月大時接種，4 至 6 歲時接種第二劑。 | [Link](https://longbridge.com/en/news/275950694.md) |
| BASF 將在路德維希港增加 BDO 的產量 | 巴斯夫支持通過在路德維希港增加生產來保障歐洲 BDO 供應安全 | [Link](https://longbridge.com/en/news/276046129.md) |
| 康寧的太陽能計劃面臨執行、政策以及市場波動的風險 | 康寧公司 (GLW) 在其太陽能業務中面臨重大風險，包括執行挑戰、合規性、供應鏈問題和市場波動。該公司對政府激勵措施的依賴以及對政策變化的敏感性可能會影響盈利能力。此外，太陽能市場的快速變化可能會妨礙長期規劃。儘管面臨這些挑戰，華爾街對 G | [Link](https://longbridge.com/en/news/275967454.md) |
| 由於 ‘醫療自由’ 的推動，美國正經歷 30 年來最嚴重的麻疹爆發，醫生們因此承受着巨大的壓力 | 美國 30 多年來最大的麻疹疫情正在南卡羅來納州爆發，報告病例超過 930 例。醫療人員正在進行户外分診，以防止病毒在診所內傳播。由於錯誤信息和對 COVID-19 措施的反對，疫苗反對情緒導致免疫接種率下降，只有 89% 的學生按時接種疫 | [Link](https://longbridge.com/en/news/275888695.md) |
| CPS Technologies Corp.（納斯達克股票代碼：CPSH）空頭頭寸顯著增長 | CPS Technologies Corp.（納斯達克代碼：CPSH）在 1 月份經歷了顯著的空頭頭寸增加，增長了 171.4%，達到 135,239 股。目前，0.9% 的股份被賣空，基於 803,142 股的平均日交易量，覆蓋天數比率為 | [Link](https://longbridge.com/en/news/275784628.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.